← Back to Clinical Trials
Recruiting NCT06206863

NCT06206863 Community-Based Physical Activity Intervention for Underserved Cancer Survivors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06206863
Status Recruiting
Phase
Sponsor Roswell Park Cancer Institute
Condition Hematopoietic and Lymphoid System Neoplasm
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2024-08-20
Primary Completion 2027-12-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Exercise InterventionQuestionnaire Administration

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2024-08-20 with a primary completion date of 2027-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This clinical trial evaluates a community-based physical activity program for underserved cancer survivors. Cancer and its treatment significantly influence physical, psychosocial, and cognitive functioning. Historically, community sites (local and national) have not been staffed to offer support services such as physical, and occupational therapies (everyday life activities to promote health and well-being) or nutrition counselling, and do not offer a whole-person model of care. In this study, researchers have partnered with the YMCA to provide tailored home-based exercise programs for underserved cancer patients and survivors. Accessing exercise professionals may allow patients to prevent acute problems from becoming chronic, long-lasting physically weak impairments that directly influence patients' quality of life.

Eligibility Criteria

Inclusion Criteria: * Have had a previous cancer diagnosis OR are a caregiver for a patient who has had a previous cancer diagnosis * Not in active treatment for cancer * Over 18 years of age Exclusion Criteria: * Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, atrial fibrillation (AFIB), multiple myeloma, or psychiatric illness/social situations that would limit compliance with study requirements * Have orthopedic or neuromuscular disorders or arthritis that preclude participation in exercise * Are pregnant or nursing * Are unwilling or unable to follow protocol requirements * Have any condition which in the investigator's opinion deems the subject an unsuitable candidate to participate in this study

Contact & Investigator

Principal Investigator

Andrew D Ray

PRINCIPAL INVESTIGATOR

Roswell Park Cancer Institute

Frequently Asked Questions

Who can join the NCT06206863 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hematopoietic and Lymphoid System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06206863 currently recruiting?

Yes, NCT06206863 is actively recruiting participants. Visit ClinicalTrials.gov or contact Roswell Park Cancer Institute to inquire about joining.

Where is the NCT06206863 trial being conducted?

This trial is being conducted at Buffalo, United States.

Who is sponsoring the NCT06206863 clinical trial?

NCT06206863 is sponsored by Roswell Park Cancer Institute. The principal investigator is Andrew D Ray at Roswell Park Cancer Institute. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology